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Introduction {#sec1}
============

The regulation of energy homeostasis, including food intake, energy expenditure, and body adiposity, is crucial to a healthy body ([@bib32], [@bib12]). Obesity is the result of an imbalance in energy homeostasis, which is caused by energy intake that exceeds energy expenditure, and excess energy is stored in fat in the form of triglycerides (TGs), leading to adiposity ([@bib47]) and causing a series of metabolic diseases, such as insulin resistance, type 2 diabetes mellitus, cardiovascular disease, cancer, inflammation, and other related diseases ([@bib45]). At present, obesity has become one of the fastest-growing non-communicable diseases, and global estimates have shown that by 2030, 38% adults would be overweight and 20% will develop obesity ([@bib34], [@bib16]). Although obesity is dire, satisfactory, safe, and effective treatment strategies are limited.

There are two main types of fat in mammals, namely, energy-storing white adipose tissues (WAT) and energy-consuming brown adipose tissues (BATs) ([@bib35]). Unlike WAT, BAT contains a large number of mitochondria, which is responsible for nonshivering thermogenesis in mammals ([@bib51], [@bib4]). Several studies have shown that the potential therapy of anti-obesity and related metabolic diseases is related to the activation of BAT ([@bib17], [@bib29], [@bib19], [@bib52]). Furthermore, proper stimulus could induce the generation of uncoupling protein-1 (UCP1) in WAT, which is also rich in mitochondria and defined as beiging ([@bib43]). Many studies have suggested that beiging in WAT can also effectively enhance energy expenditure and improve metabolic disorders ([@bib2], [@bib38]). Furthermore, reducing the amount of WAT and the size of white adipocytes can effectively improve inflammation and metabolic disorders ([@bib31]). Both WAT and BAT have essential functions in regulating energy homeostasis. Therefore, increasing BAT activation and inducing beiging in WAT could be an effective therapeutic strategy for obesity and related diseases.

SIRT1, a nuclear NAD^+^-dependent protein deacetylase ([@bib22]) that belongs to the sirtuin family (referred to as Sirt1 to Sirt7) ([@bib14]), plays a vital role in regulating transcription in various key metabolites ([@bib50]). Many studies have reported that SIRT1 can enhance BAT function and regulate metabolism ([@bib44], [@bib3], [@bib5]). PGC1α is an essential regulator of mitochondrial biogenesis ([@bib20]) that can co-activate nuclear respiratory factor-1 (NRF-1) activity at the TFAM promoter. Several studies have shown that sirt1 can regulate mitochondrial function by regulating PGC-1α and NRF pathway activity ([@bib20], [@bib47], [@bib9]). Furthermore, Sirt5, another member of the sirtuin family, which is located in mitochondria, plays an essential role in desuccinylase activity ([@bib36]). Recent studies have shown that sirt5 regulates the mitochondrial lysine succinylome ([@bib42]) and has major regulatory effects on BAT function and UCP1 activity through succinylation modification ([@bib40]). It has also been reported that sirt5 regulates the differentiation of brown adipocytes and browning of subcutaneous fat ([@bib30]). However, the regulation and function of succinylation in different tissues and organs remain unclear. More importantly, studies on the regulatory role of small molecules on sirt5 and succinylation are limited.

Emerging evidence suggests that mitophagy/autophagy plays an essential role in the physiology of the mitochondria-enriched brown and beige adipocytes, which also suggests that elucidation of the molecular links between mitophagy/autophagy and energy metabolism may facilitate in the identification of potential targets for the treatment of obesity and related metabolic disorders ([@bib26], [@bib37]). Mitophagy pertains to the selective removal of mitochondria through autophagy, which is driven by specific proteins (e.g., BNIP, FUNDC1, NIX, and BCL2L13) interacting with autophagosomal protein LC3 that drives autophagosomes and degrades its contents and is usually employed as a common marker of autophagy ([@bib1]). Furthermore, LC3II/LC3I is often used as the activation marker of autophagy ([@bib25]). Damage to the mitochondria is a major physiological trigger for mitophagy. Given the vital role of the mitochondria in the thermogenic function of brown and beige adipocytes, it is significant to investigate the mechanisms underlying the regulation of mitophagy/autophagy in thermogenic fat organs.

Allicin*,* the main bioactive ingredient in garlic ([@bib6]), has multiple pharmacological functions, including anti-oxidative stress, anti-tumor and cholesterol-lowering effects, anti-platelet aggregation, liver protection, prevention of cardiovascular disease, and anti-inflammatory capacity ([@bib8], [@bib11], [@bib23]). Although allicin induces beiging in WATs ([@bib7]), its effect on the regulation of energy homeostasis, including whole-body energy metabolism, and the mechanism of activation of BAT of allicin remains unclear. In this study, we determined the effect of allicin on whole-body energy metabolism and BAT activation and its underlying mechanism. Our results showed that allicin significantly induces the activity of the Sirt1-Pgc1α-Tfam signaling cascade and increases the generation of mitochondria in BAT. Importantly, we propose that allicin is a potential agonist of succinylation and plays a vital role in the regulation of UCP1 activity and that excessive garlic intake could impair BAT function due to the allicin-induced mitophagy in brown adipocytes. Our findings establish that allicin plays a previously not fully recognized role in regulating energy homeostasis, which may facilitate the development of a novel therapeutic approach for the treatment of metabolic disorders.

Result {#sec2}
======

Allicin Reduces Adiposity and Maintains Glucose Homeostasis in Mice {#sec2.1}
-------------------------------------------------------------------

To investigate the effect of allicin on energy homeostasis, high-fat-diet (HFD)-induced obesity and genetically leptin-receptor-deficient obese (Db/Db) mouse models were used to assess the role of allicin on obesity and energy metabolism. First, we screened the optimal treatment concentration (allicin-high 1 mg/mL, which means allicin was consumed about 4.2 mg/day per mice) of allicin by observing the effect of three doses of allicin on the reduction of body weight of HFD mice ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}B) and then treated Db/Db mice with the optimal concentration. A significant reduction in body weight after allicin treatment was observed both in HFD and Db/Db mouse models ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S2](#mmc1){ref-type="supplementary-material"}A--S2C). The protection from weight gain after allicin treatment was mainly due to the reduction in fat accumulation in epididymal WAT (eWAT) and subcutaneous WAT (sWAT) ([Figures 1](#fig1){ref-type="fig"}C--1F, [S2](#mmc1){ref-type="supplementary-material"}D, and S2E). These findings indicate that the anti-adiposity effect of allicin is evident from long-term accumulations of both innate and genetic obesity. Adiposity often affects glucose homeostasis, so glucose homeostasis and insulin resistance were analyzed by glucose tolerance test and insulin tolerance test in HFD and Db/Db mice. As expected, allicin treatment improved glucose tolerance and insulin responses ([Figures 1](#fig1){ref-type="fig"}G--1J, [S2](#mmc1){ref-type="supplementary-material"}F, and S2G). Furthermore, serum profiles, including total cholesterol (CHO), TG, low-density lipoprotein (LDL), and nonesterified fatty acid (NEFA) levels, also markedly decreased after allicin treatment in DIO mice ([Figure S3](#mmc1){ref-type="supplementary-material"}). Taken together, these results indicate that allicin notably ameliorates adiposity and maintains glucose homeostasis in mice.Figure 1Allicin Reduces Adiposity and Improves Glucose Homeostasis in DIO MiceVehicle (control) or different doses of allicin were administrated each day for a total of 13 weeks.(A) Body weight evaluation of control HFD mice or mice treated with different doses of allicin. (n = 9).(B) Body weight again of different groups of mice (n = 9).(C) Body fat percentage test using nuclear magnetic resonance.(D) Organ weight of control and allicin-treated HFD mice (n = 6).(E) H&E staining of BAT, sWAT, and eWAT sections from DIO control and allicin-treated DIO mice. Scale bars, 100 μm.(F) Quantification of the area of adipocytes in the selection of H&E sections in (E).(G and H) (G) Glucose tolerance test of control and allicin-treated DIO mice (intraperitoneally with glucose as 1.0 g/kg after 16-h fast) (n = 8). (H) The average area under the curve (n = 8).(I and J) (I) Insulin tolerance test was performed on control and allicin-treated DIO mice (injection insulin with 2.0 U/kg after 6 h of fasting (n = 8). (J) The average area under the curve (n = 8).Values represent means ± SEM. Error bars represent SEM; significant differences compared with vehicle controls are indicated by ∗p \< 0.05, ∗∗p \< 0.01(assessed by Student\'s t test). Different letters indicate signicance among groups (P\<0.05).

Allicin Augments Whole-Body Energy Expenditure by Activation of Brown Adipose Tissue {#sec2.2}
------------------------------------------------------------------------------------

Energy consumption is an essential indicator of energy homeostasis. We next investigated the effect of allicin on whole-body energy expenditure in HFD and Db/Db mice using the respiratory metabolic system. We found that allicin markedly increased oxygen consumption in both HFD and Db/Db mice ([Figures 2](#fig2){ref-type="fig"}A--2C, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B), indicating that the allicin-treated group has a higher energy expenditure. However, no significant difference in physical activity, food intake, or water intake was observed ([Figures 2](#fig2){ref-type="fig"}D-2F, and [S4](#mmc1){ref-type="supplementary-material"}C). Allicin treatment also significantly increased thermogenesis in interscapular BATs and rectal temperature after cold stimulation compared with the control HFD and Db/Db mouse groups ([Figures 2](#fig2){ref-type="fig"}G, 2H, [S4](#mmc1){ref-type="supplementary-material"}D, and S4E). BAT is well known as an essential thermogenic and energy-consuming organ in the body; it maintains body temperature by non-shaking thermogenesis with cold stimuli. Based on the above-mentioned results, we hypothesized that allicin augments whole-body energy expenditure by activating BAT in HFD and Db/Db mice. Allicin treatment also significantly induced the expression of genes related to thermogenesis and energy expenditure, including Ucp1, Prdm16, Pgc1α/β, Cpt1α, and Mcad, in the BAT from HFD mice ([Figure 2](#fig2){ref-type="fig"}I). Meanwhile, 18F-fluorodeoxyglucose positron emission tomography (PET) combined with X-ray computed tomography (CT) analysis show that allicin treatment dramatically increased the glucose utilization rate in both HFD and Db/Db mice ([Figures 2](#fig2){ref-type="fig"}J, 2K, [S4](#mmc1){ref-type="supplementary-material"}F, and S4G). Histological analysis of BAT indicates that allicin treatment reduces the size of lipid droplets ([Figures 1](#fig1){ref-type="fig"}F and [S3](#mmc1){ref-type="supplementary-material"}H). Immunoblotting analysis further indicated that allicin significantly enhances expression of UCP1 and OXPHOS-related proteins (ATP5A and NDUFB8) in BAT of both HFD and Db/Db mouse ([Figures 2](#fig2){ref-type="fig"}L, 2M, and [S3](#mmc1){ref-type="supplementary-material"}I). These results strongly indicate that allicin dramatically increases BAT activity in HFD and Db/Db mice. These results together confirm that allicin treatment increases whole-body energy expenditure and reduces adiposity in mice.Figure 2Allicin Increases Energy Expenditure and Enhances BAT Activity in DIO Mice(A--F) (A and B) Energy expenditure was assessed by oxygen consumption (VO2) in DIO mice after 12 weeks of allicin treatment (B) (n = 5); (C--F) respiratory exchange ratio (C), physical activity (D), food intake (E), and water intake (F) of control and allicin-treated DIO mice (n = 5).(G) Infrared thermal images of control and allicin-treated DIO mice, which shows more thermal signals in the interscapular BAT position.(H) The core body temperature of control and allicin-treated mice after cold stimulation (4°C for 4 h).(I) The real-time PCR analysis of thermogenic genes in BAT from control and allicin-treated DIO mice.(J--L) (J and K) PET/CT images after injection of 18F-fluorodeoxyglucose (18F-FDG) into DIO mice treated with vehicle and allicin for 12 weeks (J). White triangles indicate the anatomical site of the interscapular BAT (n = 3). Mean standard uptake value (SUV) of 18F-FDG in BAT (K). UCP1 and OXPHOS expression levels in BAT of control and allicin-treated DIO mice (L).(M) The relative protein levels of (L).Values represent the means ± SEM. Error bars represent SEM; significant differences compared with vehicle controls are indicated by ∗p \< 0.05 (assessed by Student\'s t test).

To further confirm that the anti-obesity role of allicin is mainly via regulation of BAT activation, allicin treatment was performed on diet-induced obese mice under thermoneutral condition (28°C--30°C), which will make BAT inactive. The results showed that allicin treatment did not significantly reduce body weight gain under thermoneutral conditions ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B), with no difference in food and water intake ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). In addition, thermogenesis in the mice also did not exhibit any significant improvement ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F) and the morphology of BATs did not show any activation phenotype ([Figure S5](#mmc1){ref-type="supplementary-material"}G) after allicin treatment. Simultaneously, allicin treatment did not significantly improve the fatty liver after loss of BAT activity (under thermoneutral conditions) in DIO mice. These results clearly indicate that the anti-obesity role of allicin depends more on BAT activation.

Allicin Activates the Brown Adipocytes and Increases the Energy Expenditure *In Vitro* {#sec2.3}
--------------------------------------------------------------------------------------

The above-mentioned results have proved that allicin increases energy expenditure via activation of BAT *in vivo*. However, whether allicin activates brown fat as a direct or indirect effect remains unclear. To resolve this question, we isolated brown primary adipocytes from mice and performed an *in vitro* brown adipocyte differentiation assay with or without allicin treatment. The results showed that allicin increases the expression of UCP1, which is the golden marker of BAT activation, in a dose-dependent manner and with the best activation effect at a concentration of 50 μM ([Figure 3](#fig3){ref-type="fig"}A). In addition, the thermogenic genes, including PGC1α/β and CPT1α/β, were also upregulated after allicin treatment compared with solvent treatment ([Figure 3](#fig3){ref-type="fig"}B). Furthermore, UCP1 levels were further confirmed by quantification of protein expression by immunostaining and immunoblotting ([Figures 3](#fig3){ref-type="fig"}C--3E). Furthermore, the expression levels of the OXPHOS proteins, including ATP5A, UQCRC2, SDHB, and NDUFB8, were markedly upregulated after allicin treatment compared with solvent treatment ([Figure 3](#fig3){ref-type="fig"}D-3E). Importantly, the effect of allicin on energy expenditure was assessed based on the oxygen consumption rate (OCR) in brown adipocytes. As expected, the OCR-related basal metabolic rate, ATP levels, maximum oxygen consumption, and proton leakage all markedly increased after allicin treatment compared with solvent treatment ([Figures 3](#fig3){ref-type="fig"}F--3J). We also investigated the effect of allicin on the activation of human brown adipocytes. Surprisingly, the expression levels of thermogenic genes, including UCP1, PGC1α/β, and CPT1α/β, dramatically increased after brown adipocyte differentiation cocktail medium treatment with allicin compared with solvent treatment ([Figure S6](#mmc1){ref-type="supplementary-material"}A). The expression of mitochondrial biogenic transcription factors, including NRF1, NRF2, and TFAM, were markedly upregulated in human brown adipocytes after allicin treatment ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Simultaneously, the mitochondrial copy number was obviously increased in human brown adipocytes after treatment with allicin ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Furthermore, the UCP1 levels in human brown adipocytes were further confirmed by immunoblotting and immunostaining ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E). Meanwhile, the expression levels of OXPHOS proteins in human brown adipocytes also were significantly upregulated after allicin treatment compared with solvent treatment ([Figure S6](#mmc1){ref-type="supplementary-material"}E). The results of human brown adipocytes indicated that allicin may be potentially utilized in the treatment of human metabolic diseases. Collectively, these results indicate that allicin can activate brown adipocytes and increase energy expenditure *in vitro*.Figure 3Allicin Increases the Activity of Brown Adipocytes and Oxygen Consumption *In Vitro*(A) Dose-dependent effect of allicin on UCP1 expression in primary brown adipocytes on day 6 of brown adipogenesis.(B) Thermogenic gene expression in brown adipocytes treated with 50 μM allicin or DMSO.(C) Immunofluorescence staining of UCP1 and BODIPY in brown adipocytes treated with 50 μM rutin or DMSO at day 6 of brown adipogenesis. Scale bars, 50 μm.(D--E) The protein levels of UCP1 and OXPHOS in brown adipocytes treated with DMSO or Allicin.(F) Oxygen consumption rates (OCR) at day 6 of brown adipogenesis with Allicin or DMSO treatment. (n = 5).(G--J) The OCR-related basal metabolic rate(G), ATP levels(H), maximum oxygen consumption(I), and proton leakage(J). (n = 5).Values represent means ± SEM. Error bars represent SEM; significant differences compared with vehicle controls are indicated by ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001 (assessed by Student\'s t test).

Allicin Induces Beiging in Subcutaneous WAT {#sec2.4}
-------------------------------------------

Both BAT and WAT play important roles in maintaining energy homeostasis. Based on the above-mentioned findings ([Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}), we hypothesized that allicin also could induce the activation of UCP1 in sWAT, i.e., it contributes to the induction of beiging in sWAT. First, we evaluated the expression level of the beige markers in sWAT of HFD and Db/Db mice. Interestingly, the mRNA levels of beige cell-specific markers, such as CD137, TMEM26, and TBX1, significantly increased in sWAT of HFD and Db/Db mice ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7D). Furthermore, thermogenic and fatty acid oxidation-related genes, such as UCP1, PRDM16, PGC1α/β, and CPT1α, were significantly upregulated in sWAT after allicin treatment ([Figures S7](#mmc1){ref-type="supplementary-material"}C and S7F). Beige cells also contain abundant mitochondria, similar to classical brown adipocytes. Thus, we next investigated the expression of mitochondrial biogenic transcription factors, including TFAM, NRF1, and NRF 2, and we found that their expression levels were markedly upregulated after allicin treatment ([Figures S7](#mmc1){ref-type="supplementary-material"}B and S7E). Importantly, we also investigated the effect of allicin on the induction of beiging in human white adipocytes. Surprisingly, the expression of beiging marker genes, such as CD137, TMEM26, and TBX1, significantly increased in human white adipocytes after brown adipocyte differentiation cocktail medium treatment with allicin ([Figure S8](#mmc1){ref-type="supplementary-material"}A). Moreover, the expression levels of thermogenic genes, including UCP1, PGC1α/β, and CPT1α/β, were markedly upregulated after brown adipocyte differentiation cocktail medium treatment with allicin ([Figure S8](#mmc1){ref-type="supplementary-material"}B). Also, the mitochondrial copy number was obviously increased in beige adipocyte after treatment with allicin ([Figure S8](#mmc1){ref-type="supplementary-material"}C). The UCP1 levels were further confirmed by immunostaining and immunoblotting ([Figures S8](#mmc1){ref-type="supplementary-material"}D and S8E). The expression levels of OXPHOS proteins also significantly increased after allicin treatment ([Figure S8](#mmc1){ref-type="supplementary-material"}E). These results suggest that allicin treatment may improve energy consumption by increasing beige cell formation.

Allicin Relieves Hepatic Steatosis {#sec2.5}
----------------------------------

Obesity caused by an imbalance of energy homeostasis often leads to hyperlipidemia and fatty liver. Therefore, we investigated whether allicin mediates fat reduction by preventing hyperlipidemia and hepatic steatosis in HFD and Db/Db mice. The liver mass of HFD mice markedly decreased after allicin treatment ([Figure 1](#fig1){ref-type="fig"}D). Morphology analysis also showed that liver size is smaller and the color of the liver is more biased toward normal in HFD and Db/Db mice after allicin treatment ([Figure 4](#fig4){ref-type="fig"}A). Histological analysis of H&E and oil red O staining showed that allicin treatment dramatically reduced the lipid accumulation in the liver of HFD and Db/Db mice ([Figure 4](#fig4){ref-type="fig"}A). In addition, TG content analysis showed that allicin treatment strongly inhibited liver lipid accumulation and ameliorated liver steatosis in obese mice ([Figure 4](#fig4){ref-type="fig"}B). Furthermore, the plasma levels of aspartate aminotransferase, alkaline phosphatase, and total protein markedly decreased and were closer to normal values in obese mice after allicin treatment ([Figure 4](#fig4){ref-type="fig"}C). Serum profiles, including CHO, TG, LDL, and NEFA levels, also markedly decreased in HFD mice after Allicin treatment ([Figure S3](#mmc1){ref-type="supplementary-material"}). The expression levels of fatty acid oxidation-related genes (*Sirt1, PGC1α, CPT1,* and *CPT1β*) and lipolysis-related genes (*PPARα, HSL,* and *ATGL)* significantly increased, whereas those of fatty acid synthesis (*SREBP1, ACC, FASN,* and *PPARγ*) and proinflammatory (*TNFα, IL1β,* and *IL6*) factors markedly decreased in HFD mice after allicin treatment ([Figures 4](#fig4){ref-type="fig"}D--4G). These findings indicate that allicin activates BATs and improves whole-body energy metabolism, thereby improving hepatic steatosis. However, allicin treatment did not significantly improve hepatic steatosis after losing BAT activity (under thermoneutral conditions) in DIO mice. In summary, these results indicate that allicin specifically attenuates hepatic steatosis, and BAT plays an important role in positively regulating whole-body energy metabolism in obese mice.Figure 4Allicin Relieves Hepatic Steatosis in Obese Mice(A) Liver morphology and H&E and oil red O staining from liver sections in control and allicin-treated DIO mice and Db/Db mice. Scale bars, 100 μm.(B) TG concentrations in the liver of DIO mice and Db/Db mice.(C) Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total protein (TP), and albumin (ALB) levels in control and allicin-treated DIO mice.(D--G) (D--F) Real-time PCR analysis of fatty acid oxidation-related gene (D), fatty acid synthesis-related gene (E), lipolysis-related genes (F), and inflammatory factor-related genes (G) in the liver of control and allicin-treated DIO mice.Values represent the means ± SEM. Error bars represent SEM; significant differences compared with vehicle controls are indicated by ∗p \< 0.05, ∗∗p \< 0.01 (assessed by Student\'s t test).

Allicin Enhances the Activity of SIRT1 and Activates the Downstream PGC1α-Tfam Signaling Pathway {#sec2.6}
------------------------------------------------------------------------------------------------

As shown in the previous sections, allicin upregulates sirt1 levels in the liver of obese mice. Sirt1-mediated PGC1α deacetylation and activation are essential for the generation and function of mitochondria ([@bib47]). These clues prompted us to hypothesize that allicin-induced BAT activation occurs via the Sirt1-PGC1α signaling pathway. Therefore, we next investigated the expression of sirt1 in BATs of HFD mice treated with or without allicin. The results showed that the expression levels of sirt1 did not significantly change with allicin treatment ([Figures 5](#fig5){ref-type="fig"}A and 5B). However, the downstream proteins of sirt1, including PGC1α, NRF1, and Tfam, which belong to the PGC1α-Tfam signaling pathway, were significantly upregulated after allicin treatment ([Figures 5](#fig5){ref-type="fig"}A and 5B). These results also confirm the findings of allicin treatment in brown adipocytes *in vitro* ([Figure 5](#fig5){ref-type="fig"}C). As is known, protein phosphorylation is an important post-translational modification that regulates protein activity. We next investigated the phosphorylation level of sirt1 through immunoprecipitation experiments in brown adipocytes treated with allicin using a phosphorylated pan-antibody. Interestingly, the phosphorylation level of sirt1 increased in a dose-dependent manner and coincided with the internal protein expression levels of PGC1α, Tfam, and UCP1 ([Figure 5](#fig5){ref-type="fig"}D). These results indicate that allicin influences SIRT1 activity by enhancing the phosphorylation levels of Sirt1. Then, we further investigated whether allicin regulates Sirt1 activity and the downstream PGC1α-Tfam signaling pathway *in vitro*. SIRT1 deacetylates PGC1α ([Figure 5](#fig5){ref-type="fig"}E). Importantly, allicin treatment substantially enhances the phosphorylation of sirt1 and increases Sirt1-mediated PGC1α deacetylation ([Figure 5](#fig5){ref-type="fig"}E). Conversely, knocking down Sirt1 weakens Allicin-mediated PGC1α deacetylation ([Figure 5](#fig5){ref-type="fig"}F). These results indicate that allicin increases SIRT1 deacetylase activity by enhancing its phosphorylation. Furthermore, we assessed the generation of mitochondria by analyzing mtDNA copy number and transmission electron microscopy (TEM). As expected, allicin treatment dramatically increased the number of mitochondria in BAT, as evidenced by mtDNA copy number analysis ([Figure 5](#fig5){ref-type="fig"}G) and TEM examination ([Figure 5](#fig5){ref-type="fig"}H). In addition, the absence of sirt1 inhibited the allicin-mediated increase in mtDNA copy number ([Figure 5](#fig5){ref-type="fig"}I). Collectively, these findings prove that allicin improves mitochondrial generation by activating SIRT1 and the downstream PGC1α-Tfam signaling pathway in BATs.Figure 5Allicin Promotes Mitochondrial Biogenesis through the Activation of Sirt1-PGC1α-Tfam Pathway(A) The mRNA expression of SIRT1, Tfam, and NRF1 in BAT from control and allicin-treated DIO mice.(B) Western blot analysis of the Sirt1, PGC1α, NRF1, and Tfam in BAT from control and allicin-treated DIO mice.(C) Western blot analysis of Sirt1, PGC1α, NRF1, and Tfam in brown adipocytes treated with or without allicin.(D) The phosphorylation levels of sirt1 in brown adipocytes treated with allicin at different concentrations.(E) SIRT1 deacetylates PGC1α, and allicin treatment substantially increases the phosphorylation of sirt1 and SIRT1-mediated PGC1α deacetylation.(F) In contrast, shSIRT1 treatment significantly diminishes allicin-mediated PGC1α deacetylation.(G) Mitochondrial mtDNA copy number in BAT from control and allicin-treated DIO or Db/Db mice.(H) Transmission electron microscopic (TEM) analysis of mitochondrial in BAT of control and allicin-treated DIO mice. Scale bars, 2 μm.(I) shSIRT1 treatment significantly diminishes the allicin-mediated increase in mtDNA copy number.Values represent means ± SEM. Error bars represent SEM; significant differences compared with vehicle controls are indicated by ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001 (assessed by Student\'s t test).

Allicin Enhances Succinylation of UCP1 {#sec2.7}
--------------------------------------

As mentioned earlier, sirt5 also plays critical regulatory roles in BAT function and UCP1 activity via succinylation modification ([@bib42]). However, available information on the regulation of succinylation by small molecules in food is limited. Therefore, we investigated the effect of allicin on succinylation in BATs. First, we examined the expression levels of desuccinylase-sirt5 in different adipose tissues and found that sirt5 is most abundant in BATs compared with the other two adipose tissue ([Figures 6](#fig6){ref-type="fig"}A and 6B). This indicated that BAT may be the main target organ of succinylation in adipose tissues. Furthermore, sirt5 was downregulated in the BATs of HFD mice compared with low-fat diet mice ([Figure 6](#fig6){ref-type="fig"}C), which suggests that sirt5 plays important role in BAT function during diet-induced obesity. We next found that allicin treatment markedly decreased the mRNA and protein expression levels of sirt5 both in HFD and Db/Db mice ([Figures 6](#fig6){ref-type="fig"}D and 6E). This result indicates that allicin treatment enhances the succinylation levels of certain proteins in BAT. Furthermore, immunoblotting analysis using a pan-succinylation antibody indicates that allicin treatment increases the succinylation levels of various proteins in BATs and brown adipocytes ([Figures 6](#fig6){ref-type="fig"}F and 6G). At this point, we wanted to determine which proteins had undergone succinylation modification. Surprisingly, we identified the changed succinylation levels of UCP1 from a series of pulled-down proteins in BATs through label-free proteomics analysis of allicin-treated and HFD control mice ([Figure 6](#fig6){ref-type="fig"}H). Then, we further confirmed that the succinylation levels of UCP1 significantly increase after allicin treatment of brown adipocytes ([Figure 6](#fig6){ref-type="fig"}I). Furthermore, the increase in succinylation levels of UCP1 depends on the dosage of allicin both in mouse and human brown adipocytes ([Figures 6](#fig6){ref-type="fig"}J and [S6](#mmc1){ref-type="supplementary-material"}F).Figure 6Allicin Upregulates Succinylation Levels in BAT by Inhibiting sirt5(A and B) Sirt5 expression levels in eWAT, sWAT, and BAT in mice.(C and D) (C) The protein expression levels of Sirt5 in BAT in low-fat diet and HFD mice. (D) Sirt5 expression levels in BAT from control and allicin-treated DIO mice.(E) Sirt5 expression levels in BAT from control and allicin-treated Db/Db mice.(F) Protein succinylation levels in BAT from control and allicin-treated DIO mice.(G) The protein succinylation levels in brown adipocytes treated with or without allicin.(H) Schematic diagram of the process of label-free proteomic analysis.(I) Allicin treatment increases the succinylation levels of UCP1 in brown adipocytes by immunoprecipitation analysis.(J) Succinylation levels of UCP1 increase in brown adipocyte after allicin treatment and in a dose-dependent fashion.Values represent means ± SEM. Error bars represent SEM; significant differences compared with vehicle controls are indicated by ∗∗p \< 0.01 (assessed by Student\'s t test).

Excess Allicin Induces Mitophagy in Brown Adipocytes {#sec2.8}
----------------------------------------------------

Allicin treatment also upregulates succinylation-related proteins in a concentration-dependent manner ([Figure 7](#fig7){ref-type="fig"}A). These results suggest that allicin may be an activator of succinylation. Previous reports have indicated that the excessive accumulation of succinylation results in impairment of BAT function ([@bib42]). This implies that allicin treatment using excessive amounts may cause BAT dysfunction. Dose-dependent allicin treatment of brown adipocytes results in the gradual deterioration of cell morphology, whereas the level of succinylation of proteins gradually increased ([Figures 7](#fig7){ref-type="fig"}A and 7B). Meanwhile, the mRNA expression levels of UCP1 gradually decreased with increasing allicin concentrations, particularly after exceeding the optimal concentration ([Figure 7](#fig7){ref-type="fig"}C). Moreover, treatment with excessive amounts of allicin (500 μM) triggered the expression of autophagy/mitophagy markers, whereas diminished the expression of mitochondrial Oxphos-related genes in brown adipocytes ([Figures 7](#fig7){ref-type="fig"}D and 7E). Notably, allicin treatment using a moderate concentration (50 μM) did not induce the expression of autophagy/mitophagy markers, but it dramatically stimulated the expression of mitochondrial Oxphos-related genes ([Figures 7](#fig7){ref-type="fig"}D and 7E). These results suggest that treatment with excessive amounts of allicin may induce mitophagy, impair mitochondrial homeostasis, and decrease the number of mitochondria in brown adipocytes. LC3II/LC3I is a biomarker of autophagy activation. Interestingly, we found that treatment with excessive amounts of allicin promotes autophagy/mitophagy and decreases the number of mitochondria. Conversely, Sirt5 overexpression can partly rescue these phenotypes ([Figures 7](#fig7){ref-type="fig"}F and 7G). This indicated that excessive amounts of allicin induce mitochondrial dysfunction partly through the suppressed sirt5-mediated succinylation accumulation in brown adipocytes. All the above-mentioned results suggest that allicin has dual functions, and treatment with excessive amounts may disrupt energy homeostasis. Although allicin imparts a positive effect on regulating energy homeostasis, treatment with excessive amounts may lead to a disorder of energy metabolism due to the dysfunction of BAT. Our findings thus provide useful information and theoretical basis for the rational use of allicin as a safer, more effective, and valuable molecule for the treatment of metabolic diseases.Figure 7Excessive Amounts of Allicin Induce Mitophagy in Brown Adipocytes(A) The succinylation levels of general proteins in brown adipocytes with dose-dependent allicin treatment.(B) The morphology of brown adipocytes treated with different doses of allicin. Scale bars, 50 μm.(C) mRNA expression levels of UCP1 in brown adipocytes treated with different doses of allicin.(D) Real-time PCR analysis of autophagy/mitophagy marker genes in brown adipocytes treated with different doses of allicin (0, 50, and 500 μM).(E) Real-time PCR analysis of mitochondrial Oxphos-related genes in brown adipocytes treated with different doses of allicin (0, 50, and 500 μM).(F) Overexpression of Sirt5 effectively rescued the high-dose allicin-mediated increase in LC3 in brown adipocytes.(G) Overexpression of Sirt5 effectively rescues the high-dose allicin-mediated decrease in mitochondrial mtDNA copy number in brown adipocytes.Values represent means ± SEM. Error bars represent SEM; significant differences compared with vehicle controls are indicated by ∗p \< 0.05 (assessed by Student\'s t test). Different letters indicate signicance among groups (P\<0.05).

Discussion {#sec3}
==========

Metabolic diseases caused by the imbalance in energy homeostasis are collectively considered as epidemics, particularly obesity and related metabolic diseases. BAT is a critical organ that regulates energy homeostasis and is known as an important potential target for the treatment of metabolic diseases ([@bib19]). Bioactive compounds in food have attracted much attention as a safe and effective molecular library. It has been reported that garlic is an excellent natural source of bioactive compounds ([@bib15]). In this study, we revealed the beneficial effects of allicin on energy homeostasis in obese mice. Our data show that allicin enhances BAT function, promotes the energy expenditure, inhibits the fat mass accumulation, improves the glucose homeostasis and insulin sensitivity, and alleviates hepatic steatosis. Allicin promotes the activity of sirt1 and induces the downstream PGC1α-Tfam signaling pathway. This is the first study that relatively systematically demonstrates that allicin induces BAT activation and regulates energy homeostasis. Our findings show that administration of allicin using appropriate concentrations may potentially be a therapeutic strategy for obesity and related metabolic syndromes.

Allicin (thio-2-propene-1-sulfinic acid S-allyl ester) is the principal component of garlic and has many physiological functions. Several studies have reported that garlic or its main ingredient, allicin, have anti-oxidation, anti-obesity, anti-hyperinsulinemic, anti-hyperlipidemic, and anti-hypertensive effects ([@bib23], [@bib10], [@bib18]). Among these, a research article reported that allicin could induce brown-like adipogenesis and increase lipid oxidation in subcutaneous fat though KLF15 signal cascade ([@bib23]). However, the effect and mechanism of allicin on BAT functions have remained unclear. In addition, research on allicin in relation to regulating energy homeostasis is limited. The present study demonstrated that allicin induces BAT activation, leading to the inhibition of obesity and maintenance of energy homeostasis in mice.

Malfunctions in energy homeostasis, including energy expenditure, food intake, and fat hypertrophy, can cause obesity ([@bib32], [@bib12]). In the current study, allicin treatment profoundly increased energy expenditure, reduced fat mass, caused body weight gain, and improved the glucose homeostasis in HFD mice. Importantly, a similar effect was further confirmed in Db/Db mice, which is a leptin receptor-deficient genetic obese mice model. This indicates that allicin prevents and alleviates obesity as well as regulates energy metabolism in the body. Furthermore, we investigated the effect of allicin on BAT activation both in HFD and Db/Db mice and found that allicin treatment more profoundly promotes the activation of BAT in Db/Db mice than in HFD mice ([Figures 2](#fig2){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}), based on the fact that Db/Db mice are deficient in BAT activity ([@bib41]). This result indicates that allicin activates BAT and regulates energy metabolism. However, several factors (including thyroid hormones, catecholamine neurotransmission, and cytokines) are secreted by the endocrine system, which can activate brown adipocytes. So, to determine whether the effect of allicin on BAT activation is direct or secondary, *in vitro* allicin treatment of brown adipocytes was performed, which confirmed that allicin could directly activate brown adipocytes.

Information on the effects of allicin on human metabolism is limited, and it is difficult to accurately predict whether the effect of allicin in the human body is similar to that in animals. In our study, we treated human brown adipocytes with allicin and found that it can also dramatically increase the expression levels of UCP1 and related thermogenic genes. This result suggests that allicin may be potentially utilized in regulating energy homeostasis by activating BATs in the human body. Moreover, our findings may serve as reference for future studies on allicin in relation to human metabolic disease. Accumulating evidence has proved that the beiging of WAT is also a critical strategy for the treatment of obesity ([@bib47], [@bib39]). Consistent with these previous reports, we also found that allicin can induce beige fat formation and markedly increase the expression of beige markers in the subcutaneous fat of HFD mice and Db/Db mice. Importantly, we also further confirmed the beiging induction effect of allicin in human white adipocytes. These results suggest that thermogenic fats, including BAT and beige fat, have a positive regulatory effect on energy homeostasis.

Hepatic steatosis is also a typical phenotype of imbalanced energy homeostasis ([@bib46]). Nonalcoholic fatty liver (NAFLD) is caused by metabolic syndrome often accompanied by hyperlipidemia, obesity, and related type 2 diabetes ([@bib28]). Several studies have reported that garlic and its essential ingredients could protect against NAFLD by regulating lipid metabolism ([@bib21], [@bib24]). Consistently, our data also confirm that allicin could significantly ameliorate lipid accumulation in the liver of HFD and Db/Db mice. In addition, we found that allicin treatment can markedly increase the mRNA expression levels of fatty acid oxidation- and lipolysis-related genes, whereas downregulate the fatty acid synthesis-related and proinflammatory genes. Given the effect of allicin on whole-body energy metabolism by activation of BAT, we hypothesis that the phenotype of improvement of NAFLD in mice is more responsible for the enhanced whole-body energy expenditure and the improved metabolic condition caused by the activation effect of allicin on thermogenic fat. Interestingly, we found that allicin treatment does not significantly inhibit body weight gain under thermoneutral conditions ([Figure S5](#mmc1){ref-type="supplementary-material"}). Simultaneously, allicin treatment did not significantly improve fatty liver after loss of BAT activity (under thermoneutral conditions) in DIO mice ([Figure S5](#mmc1){ref-type="supplementary-material"}G). The above-mentioned results suggest that the anti-obesity role of allicin depends more on the role of BAT activation. However, *in vitro* hepatocyte models require further in-depth analysis.

Allicin is a product obtained from alliin in the presence of alliinase ([@bib10]). Recently, we have shown that alliin did not activate BAT and had no significant effect on adiposity or energy metabolism ([@bib49]). This study confirms that allicin instead of alliin activates brown fat. Allicin and alliin have similar chemical structures; however, their functions significantly vary. Functional differences caused by their molecular structure require further investigation. The identification and allosteric study of the functional groups of allicin may significantly promote the potential utilization of allicin for the treatment of metabolic diseases.

Mitochondria are the main organelles wherein brown fat regulates energy metabolism ([@bib17]). In the current study, allicin treatment markedly increased mitochondrial copy number and upregulated OXPHOS proteins in BAT and sWAT in obese mice. In addition, allicin treatment improved the adaptive thermogenic capacity of both HFD and Db/Db mice. PET-CT confirms that allicin treatment enhances glucose uptake and utilization in BAT of obese mice. These results indicate that allicin increases energy metabolism by enhancing mitochondrial function. Recently, it has been reported that adipose tissue-specific sirt1 transgenic mice enhances whole-body energy metabolism and improves insulin resistance ([@bib44]). Phosphorylation of SIRT1 increases its stability, thereby increasing Sirt1 activity ([@bib13], [@bib33]). PGC1α, a potent regulator of mitochondrial biogenesis, can positively be regulated by SIRT1 ([@bib20]). In addition, the activation of SIRT1 can effectively decrease the acetylation of PGC1α, thereby increasing PGC1α activity ([@bib47]). Rutin, a small-molecule compound in food, has been demonstrated to enhance BAT function by increasing mitochondrial biogenesis via activation of the Sirt1-PGC1α-Tfam pathway ([@bib47]). In our study, allicin increased the phosphorylation of SIRT1 protein. Furthermore, our results show that allicin improves SIRT1-mediated PGC1α deacetylation, whereas a deficiency in SIRT1 diminishes allicin-mediated PGC1α deacetylation and offsets the increase in mitochondrial copy number with allicin treatment. In addition, allicin treatment markedly boosted PGC1α and Tfam expression in thermogenic fats from both HFD and Db/Db mice. Collectively, our findings suggest that allicin promotes BAT function partly via the SIRT1-PGC1α-TFAM pathway.

Sirt5, another member of sirtuins, has been reported to regulate several new types of post-transcriptional modifications such as malonylation, succinylation, and glutarylation ([@bib9]). Simultaneously, sirt5 can regulate the mitochondrial function though the desuccinylation of proteins in mitochondria ([@bib36]). Knockout of sirt5 induced the dysfunction of BAT due to the excessive accumulation of succinylation of UCP ([@bib42]). This study is the first to determine that allicin treatment can significantly decrease the expression levels of sirt5 and correspondingly increase the succinylation levels of UCP1 in BAT and brown adipocytes. It is worth noting that the expression level of sirt5 may be affected by the duration of HFD. We also observed that allicin treatment increases the succinylation of UCP1 in a dose-dependent manner; meanwhile the brown adipocytes lost their normal morphology and had UCP1 expression inhibited as the dose increases. Furthermore, excess allicin treatment (500 μM) markedly stimulated autophagy/mitophagy and diminished mitochondrial Oxphos, whereas a moderate allicin concentration (50 μM) upregulated mitochondrial Oxphos-related genes to levels similar to that of autophagy/mitophagy markers ([Figures 7](#fig7){ref-type="fig"}D and 7E). Conversely, Sirt5 overexpression partly rescued the above-mentioned phenotypes ([Figures 7](#fig7){ref-type="fig"}F and 7G). It indicated that sirt5 is involved in allicin-mediated regulation of mitochondrial homeostasis in brown adipocytes. These findings suggest that excessive or unnecessary allicin treatment disrupts the function of BAT by increasing succinylation levels. These findings suggest that allicin has a dual function. Similar to the yin and yang of the function of things, only moderate applications can play their best function ([Figure 8](#fig8){ref-type="fig"}).Figure 8A Proposed Model of the Mechanism by Which Allicin Regulates Mitochondrial Homeostasis in Brown AdipocytesAllicin promotes the phosphorylation of sirt1 and then activates the PGC1α-Tfam pathway, thereby increasing mitochondrial biogenesis and resulting in increased thermogenesis and fatty acid oxidation. However, allicin treatment at high doses could induce mitophagy due to the increase in succinylation in the mitochondria of brown adipocytes due to the inhibition of sirt5, resulting in mitochondrial dysfunction. These results indicate that allicin plays dual roles, similar to yin and yang properties.

Some aspects relating to the mechanism of action of allicin remain unclear, such as how sirt5 regulates mitophagy and induces mitochondrial dysfunction. We screened two candidate proteins (HSP70 and SOD2) that can undergo succinylation modification after allicin treatment in our pull-down sequence result (data not shown), and their functions may be related to the occurrence of autophagy. SOD2 can regulate autophagy via mitochondrial reactive oxygen species (ROS) ([@bib27]). Interestingly, a recent study has shown that Hsp70 modulates SOD2 activity by promoting the import of SOD2 into mitochondria, which indicates that Hsp70 has a physiological mechanism that is essential for the regulation of mitochondrial redox balance ([@bib48]). Thus, HSP70 and SOD2 may undergo overmuch succinylation modification after allicin treatment at excessively high concentrations, which may impair their regulation of mitochondrial ROS and in turn induce autophagy/mitophagy. However, we also hypothesize that the inhibition of sirt5 may cause extensive succinylation of mitochondrial proteins, which in turn disrupt mitochondrial function and induce mitophagy, including synergy of various mitochondrial proteins. So, this phenotype should not be controlled by a single or couple proteins but may partly contribute to this phenotype.

In summary, the present study demonstrated that allicin regulates energy homeostasis by promoting BAT activation partly via the SIRT1-PGC1α-TFAM pathway. Our findings also provide evidence suggesting that allicin promotes succinylation by inhibiting sirt5, and that allicin treatment at excessively high concentrations disrupts mitochondrial homeostasis. Thus, we propose the concept of yin and yang for allicin function. In general, the application of allicin at a moderate concentration may be potentially used as a novel strategy for the prevention and/or treatment of obesity and related metabolic disorders.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Limitations of the Study {#sec4.1}
------------------------

In this study, the mechanism by which allicin downregulates Sirt5 is unclear. It may be a direct or indirect regulation, such as allicin-induced DNA or RNA changes in the level of epigenetic modification, which needs to be further studied in the future. Besides, a recent report showed that allicin induces browning in WAT via KLF15 signaling ([@bib23]). In our study, we did not investigate the contribution of KLF15 signaling in BAT, even though this is an interesting point. Notably, our research does not rule out other alternative mechanisms of the anti-obesity effects of allicin, such as increased energy expenditure via improvement of gut microbiota, reduced adipocyte hypertrophy via modulation of angiogenesis, induced activation of BAT via KLF15 signaling, and reduced adipogenesis and inflammation. Moreover, the concentration of allicin may be confusing or unnecessary to reach 500 μm *in vivo*, whereas *in vitro* studies are difficult to directly link to *in vivo* studies. At least our study hints that allicin has the possibility of disturbing mitochondrial function through regulation of succinylation. So, the stimulation of Allicin *in vivo* or at the tissue level needs to be further studied.
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